Abstract
The fibrosis that occurs in the kidney is a common complication of diabetes, and a major cause of end stage renal disease (ESRD). Our laboratory has been active in identifying factors responsible for its initiation. However, a lack of understanding of the downstream regulatory pathways has prevented development of specific anti-fibrotic therapies. CCN2 (CTGF) has emerged as a critical molecule acting downstream of TGF-β to drive fibrosis, making it an exciting new therapeutic target. However, suppression of CCN2 has been difficult. In this study, we examined the possibility that CCN3 (NOV), might act as an endogenous negative regulator of CCN2 with the capacity to limit the overproduction of extracellular matrix (ECM), and thus prevent, or ameliorate fibrosis. We demonstrate, using an in vitro model of diabetic renal fibrosis, that both exogenous treatment and transfection with the over-expression of the CCN3 gene in mesangial cells markedly down-regulates CCN2 activity and blocks ECM over-accumulation stimulated by TGF-β. Conversely, TGF-β treatment reduces endogenous CCN3 expression and increases CCN2 activity and matrix accumulation, indicating an important, novel yin/yang effect. Using the db/db mouse model of diabetes, we confirm the expression of CCN3 in the kidney, with temporal localization that supports these in vitro findings. In summary, the results support our hypothesis that CCN3 has a negative regulatory action on CCN2 and the effects of TGF-β, acting to limit ECM turnover and fibrosis in vivo. The findings suggest opportunities for novel endogenous-based therapy either by the administration, or the upregulation of CCN3.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdel-Wahab N., Weston B.S., Roberts T., Mason R.M. (2002). Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol 13(10): 2437–2445.
Bollineni J.S., Reddi A.S. (1993). Transforming growth factor-beta 1 enhances glomerular collagen synthesis in diabetic rats. Diabetes 42(11): 1673–1677.
Breyer M.D., Bottinger E., Brosius F.C., 3rd, Coffman T.M., Harris R.C., Heilig C.W., et al. (2005). Mouse models of diabetic nephropathy. J Am Soc Nephrol 16(1): 27–45.
Brigstock D.R., Goldschmeding R., Katsube K.I., Lam S.C., Lau L.F., Lyons K., et al. (2003). Proposal for a unified CCN nomenclature. Mol Pathol 56(2): 127–128.
Brigstock D.R., Steffen C.L., Kim G.Y., Vegunta R.K., Diehl J.R., Harding P.A. (1997). Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids. Identification as heparin-regulated Mr 10,000 forms of connective tissue growth factor. J Biol Chem 272(32): 20275–20282.
Chevalier G., Yeger H., Martinerie C., Laurent M., Alami J., Schofield P.N., et al. (1998). novH: differential expression in developing kidney and Wilm’s tumors. Am J Pathol 152(6): 1563–1575.
Chomczynski P., Sacchi N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1): 156–159.
Cooker L.A., Peterson D., Rambow J., Riser M.L., Riser R.E., Najmabadi F., et al. (2007). TNF-{alpha}, but not IFN-{gamma}, regulates CCN2 (CTGF), collagen type I, and proliferation in mesangial cells: possible roles in the progression of renal fibrosis. Am J Physiol Renal Physiol 293(1): F157–F165.
Glukhova L., Angevin E., Lavialle C., Cadot B., Terrier-Lacombe M.-J., Perbal B., et al. (2001). Patterns of specific genomic alterations associated with poor prognosis in high-grade renal cell carcinomas. Cancer Genet Cytogenet 130(2): 105–110.
Guha M., Xu Z.G., Tung D., Lanting L., Natarajan R. (2007). Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. Faseb J 21: 3355–3368.
Gupta R., Hong D., Iborra F., Sarno S., Enver T. (2007). NOV (CCN3) functions as a regulator of human hematopoietic stem or progenitor cells. Science 316(5824): 590–593.
Hahn A., Heusinger-Ribeiro J., Lanz T., Zenkel S., Goppelt-Struebe M. (2000). Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. J Biol Chem 275(48): 37429–37435.
Hostetter T.H. (1995). Progression of renal disease and renal hypertrophy. Annu Rev Physiol 57: 263–278.
Kyurkchiev S., Yeger H., Bleau A.M., Perbal B. (2004). Potential cellular conformations of the CCN3(NOV) protein. Cell Commun Signal 2(1): 9.
Liu C., Liu X.-J., Crowe P.D., Kelner G.S., Fan J., Barry G., et al. (1999). Nephroblastoma overexpressed gene (NOV) codes for a growth factor that induces protein tyrosine phosphorylation. Gene 238(2): 471–478.
McCallum L., Price S., Planque N., Perbal B., Pierce A., Whetton A.D., et al. (2006). A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 108(5): 1716–1723.
Niu Z., Ito M., Awakura Y., Takahashi T., Nakamura E., Ito N., et al. (2005). The expression of NOV and WT1 in renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. J Urol 174(4 Pt 1): 1460–1462.
Okada H., Kikuta T., Kobayashi T., Inoue T., Kanno Y., Takigawa M., et al. (2005). Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 16(1): 133–143.
Perbal B. (2001). The CCN family of genes: a brief history. Mol Pathol 54(2): 103–104.
Perbal B. (2004). CCN proteins: multifunctional signalling regulators. Lancet 363(9402): 62–64.
Perbal B., Martinerie C., Sainson R., Werner M., He B., Roizman B. (1999). The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proc Natl Acad Sci U S A 96(3): 869–874.
Poncelet A.C., de Caestecker M.P., Schnaper H.W. (1999). The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int 56(4): 1354–1365.
Rachfal A.W., Brigstock D.R. (2005). Structural and functional properties of CCN proteins. Vitam Horm 70: 69–103.
Riser B.L., Cortes P. (2001). Connective tissue growth factor and its regulation: a new element in diabetic glomerulosclerosis. Ren Fail 23(3–4): 459–470.
Riser B.L., Cortes P., DeNichilo M., Deshmukh P.V., Chahal P.S., Mohammed A.K., et al. (2003). Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int 64(2): 451–458.
Riser B.L., Cortes P., Yee J. (2000). Modelling the effects of vascular stress in mesangial cells. Curr Opin Nephrol Hypertens 9(1): 43–47.
Riser B.L., Cortes P., Yee J., Sharba A.K., Asano K., Rodriguez-Barbero A., et al. (1998). Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-beta. J Am Soc Nephrol 9(5): 827–836.
Riser B.L., Denichilo M., Cortes P., Baker C., Grondin J.M., Yee J., et al. (2000). Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11(1): 25–38.
Riser B., Foroni A., Karoor S. (2006). CCN2 (CTGF) in the pathogenesis of diabetic renal disease: a target for therapeutic intervention. In C. Morgensen P. Cortes (Eds.), The kidney and diabetes mellitus (Sixth ed.) pp. 175–186. Kluwer Academic Publishers, Boston, MA.
Riser B.L., Ladson-Wofford S., Sharba A., Cortes P., Drake K., Guerin C.J., et al. (1999). TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int 56(2): 428–439.
Riser B.L., Najmabadi, F., Perbal, B., Peterson D.R., Rambow, V., Riser, M.L., Sukowski, E., Yeger, H., and Riser, S.C. (2009). CCN3 (Nov) is a negative regulator od CCNZ (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 174(5): 1725–1734.
Riser B.L., Varani J., Cortes P., Yee J., Dame M., Sharba A.K. (2001). Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence: a possible new mechanism for glomerulosclerosis. Am J Pathol 158(1): 11–17.
van Roeyen C.R., Eitner F., Scholl T., Boor P., Kunter U., Planque N., et al. (2008). CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 73: 86–94.
Thomopoulos G.N., Kyurkchiev S., Perbal B. (2001). Immunocytochemical localization of NOVH protein and ultrastructural characteristics of NCI-H295R cells. J Submicrosc Cytol Pathol 33(3): 251–260.
Yokoi H., Mukoyama M., Nagae T., Mori K., Suganami T., Sawai K., et al. (2004). Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 15(6): 1430–1440.
Ziyadeh F.N. (2004). Mediators of diabetic renal disease: the case for TGF-b as the major mediator. J Am Soc Nephrol 15(1, Suppl. 1): S55–S57.
Acknowledgments
We thank Dr. William Snapper at Northwestern University for providing the col1a2 construct. This work was supported by Grants from the American Diabates Association and The Juvenile Diabetes Foundation International (BLR).
The research in BP’s laboratory at the University Paris 7 D. Diderot was funded by a European contract ‘PROTHETS (Prognosis and therapeutic targets of Ewing’s family of tumours) FP6 contract number 503036’ and the French ministry of Education.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Riser, B.L. et al. (2010). CCN3 (NOV): A Negative Regulator of CCN2 (CTGF) Activity and an Endogenous Inhibitor of Fibrosis in Experimental Diabetic Nephropathy. In: Perbal, A., Takigawa, M., Perbal, B. (eds) CCN Proteins in Health and Disease. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-3779-4_13
Download citation
DOI: https://doi.org/10.1007/978-90-481-3779-4_13
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-3778-7
Online ISBN: 978-90-481-3779-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)